Why Particle Characterisation Matters in Drug Development
The pharmaceutical industry faces mounting pressure to deliver effective therapies faster, at lower cost and with greater patient safety. At the heart of this challenge lies a deceptively simple question: how well do we understand the physical properties of the active pharmaceutical ingredients (APIs) and excipients that make up a drug product? Particle characterisation provides the answer, offering critical insights into particle size distribution, morphology, surface area and charge β all of which profoundly influence a drug's solubility, stability and bioavailability.
Modern particle size analyzers such as the Mastersizer 3000+ use laser diffraction to measure particle size distributions across a wide dynamic range, from hundreds of nanometres to several millimetres. This capability is essential for formulators who need to control the dissolution rate of oral solid dosage forms, optimise inhalation therapies or ensure the uniformity of injectable suspensions.
From Discovery to Manufacturing: A Continuous Thread
Particle characterisation is not a one-off measurement; it is a continuous thread running from early discovery through to commercial manufacturing. During the discovery phase, researchers use dynamic light scattering (DLS) instruments like the Zetasizer Advance to evaluate nanoparticle candidates and assess the polydispersity index (PDI) of colloidal formulations. A low PDI signals a uniform particle population β a critical quality attribute for liposomal drug delivery systems and mRNA-based vaccines.
As candidates progress into pre-clinical and clinical development, the focus shifts to process understanding. Laser diffraction and automated imaging techniques help formulators answer pivotal questions:
- How does milling duration affect the particle size distribution of a micronised API?
- What is the optimal ratio of fine-to-coarse particles for a dry-powder inhaler blend?
- Does wet granulation alter the morphology of excipient particles in a way that impacts tablet compressibility?
By answering these questions early, development teams can reduce the number of failed batches, shorten time-to-clinic and build a robust design space that satisfies regulatory expectations under the Quality by Design (QbD) framework.
Ensuring Bioavailability Through Particle Engineering
Bioavailability β the fraction of an administered dose that reaches systemic circulation β is strongly governed by particle size. Poorly soluble compounds classified as BCS Class II or IV present particular challenges. Reducing particle size increases the specific surface area available for dissolution, thereby improving the rate and extent of drug absorption in the gastrointestinal tract. Techniques such as jet milling, wet media milling and spray drying are routinely used to produce micronised or nanosized API particles.
However, particle engineering is a balancing act. Excessively fine particles may exhibit poor flowability, increased electrostatic charge or a tendency to agglomerate, all of which compromise downstream manufacturing performance. The FT4 Powder Rheometer provides direct measurements of powder flow, compressibility and permeability, enabling formulators to quantify these risks and select processing conditions that deliver both the desired particle size and acceptable powder handling behaviour.
Regulatory Expectations and Data Integrity
Regulatory agencies including the FDA, EMA and PMDA increasingly expect applicants to demonstrate thorough understanding of how material attributes β including particle size β affect drug product performance. The ICH Q6A guideline explicitly recommends particle size specifications for drug substances where size is critical to dissolution, bioavailability or content uniformity. Instruments that deliver 21 CFR Part 11-compliant data management, automated audit trails and method validation capabilities are therefore essential components of a modern pharmaceutical quality system.
Malvern Panalytical's software platforms support Standard Operating Procedures (SOPs) with locked methods, user access controls and electronic signatures, ensuring that every measurement is traceable and every result defensible during regulatory inspection.
Looking Ahead: Continuous Manufacturing and Real-Time Release
The industry is moving steadily toward continuous manufacturing, where real-time process analytical technology (PAT) replaces traditional end-of-batch testing. In-line and on-line particle size analysers integrated directly into blending, granulation and coating equipment enable manufacturers to detect deviations within seconds rather than hours. This shift promises higher yields, lower waste and ultimately faster access to life-saving medicines for patients worldwide.
Particle characterisation is no longer a supporting measurement β it is a strategic capability that underpins every stage of modern drug development. By investing in the right analytical tools and expertise, pharmaceutical companies can accelerate innovation while maintaining the rigorous quality standards that patients and regulators demand.